We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed at $44.51 in the latest trading session, marking a -2.35% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 1.05%.
Shares of the medical device manufacturer witnessed a gain of 1.47% over the previous month, trailing the performance of the Medical sector with its gain of 3.5%, and outperforming the S&P 500's gain of 0.97%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on October 28, 2026. On that day, Boston Scientific is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 1.33%. Our most recent consensus estimate is calling for quarterly revenue of $5.17 billion, up 2.12% from the year-ago period.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.24 per share and revenue of $21.17 billion. These results would represent year-over-year changes of +5.88% and +5.45%, respectively.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.89% lower. Boston Scientific currently has a Zacks Rank of #4 (Sell).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 14.08. This represents a discount compared to its industry average Forward P/E of 20.56.
Meanwhile, BSX's PEG ratio is currently 1.1. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.88.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 158, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Boston Scientific (BSX - Free Report) closed at $44.51 in the latest trading session, marking a -2.35% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 1.05%.
Shares of the medical device manufacturer witnessed a gain of 1.47% over the previous month, trailing the performance of the Medical sector with its gain of 3.5%, and outperforming the S&P 500's gain of 0.97%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on October 28, 2026. On that day, Boston Scientific is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 1.33%. Our most recent consensus estimate is calling for quarterly revenue of $5.17 billion, up 2.12% from the year-ago period.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.24 per share and revenue of $21.17 billion. These results would represent year-over-year changes of +5.88% and +5.45%, respectively.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.89% lower. Boston Scientific currently has a Zacks Rank of #4 (Sell).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 14.08. This represents a discount compared to its industry average Forward P/E of 20.56.
Meanwhile, BSX's PEG ratio is currently 1.1. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.88.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 158, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.